U.S. Markets close in 4 hrs 31 mins

Prelude Therapeutics Incorporated (PRLD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.43-0.09 (-0.51%)
As of 11:29AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close17.52
Bid17.38 x 1300
Ask17.52 x 800
Day's Range17.39 - 18.32
52 Week Range15.31 - 95.38
Avg. Volume480,700
Market Cap817.411M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est61.60
  • TipRanks

    Morgan Stanley: Buy These 2 Stocks Before They Jump 80% (Or More)

    After slipping through September, markets have been trending up again in October. One possible reason: better-than-expected results from the Q3 earnings reports so far. With results in from 41 companies listed on the S&P 500, aggregate earnings are up more than 40% year-over-year. These solid results come even as revenues are down 13% yoy. Of the companies that have reported so far, 85% beat the anticipated EPS, while 70% beat on revenues. With these results, it should come as no surprise to see

  • Benzinga

    Mid-Afternoon Market Update: Crude Oil Rises 1%; New Fortress Energy Shares Spike Higher

    Toward the end of trading Thursday, the Dow traded up 1.29% to 34,860.01 while the NASDAQ rose 1.47% to 14,714.54. The S&P also rose, gaining 1.22% to 4,416.63. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 44,059,040 cases with around 707,780 deaths. India confirmed a total of at least 33,894,310 cases and 449,850 deaths, while Brazil reported over 21,516,960 COVID-19 cases with 599,350 deaths. In total, there were at least 236,571,580 cases

  • Benzinga

    Why Did Prelude Therapeutics Stock Tumble To 52-Week Low Today?

    Prelude Therapeutics Inc (NASDAQ: PRLD) has announced data from the dose-escalation portions of Phase 1 trials of PRT543 and PRT811. The data will be featured at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. PRT543 demonstrated target engagement and inhibition of PRMT5 functional activity, evidenced by a 69% reduction in serum symmetric dimethylarginine (sDMA) at a dose of 45 mg/5x per week. One complete response (CR) was maintained for over 18